HydraFacial v. Luvo Medical: Consent Judgment & Permanent Injunction in 357 Days
HydraFacial LLC secured a consent judgment and permanent injunction against Luvo Medical Technologies, Clarion Medical Technologies, Eunsung Global Corp, and Healthcare Markets Inc. over six hydrodermabrasion patents. The defendants are barred from selling or importing the Bela MD and Bela MD+ products through March 2026, with each party bearing its own costs.
HydraFacial locks down six-patent portfolio with injunction against Bela MD line
On August 16, 2024, HydraFacial LLC filed suit in the U.S. District Court for the District of Utah against Luvo Medical Technologies, Clarion Medical Technologies Inc., Eunsung Global Corp, and Healthcare Markets Inc., asserting infringement of six U.S. patents — Nos. 9,550,052; 11,446,477; 11,865,287; 12,053,607; 10,357,641; and 10,357,642 — covering hydrodermabrasion devices and methods. The accused products were the Bela MD and Bela MD+ systems distributed across the defendant entities.
The case closed on August 8, 2025, when Judge Tena Campbell entered a Final Consent Judgment and Permanent Injunction following a joint motion filed by the parties on August 7, 2025. Under the consent judgment, defendants are permanently enjoined through March 29, 2026 from making, using, selling, offering for sale, or importing the Bela MD and Bela MD+ products or any colorably similar product into the United States. Defendants take nothing by way of the judgment, and all remaining claims and counterclaims were dismissed without prejudice. Each party waived appellate rights.
At 357 days, the case resolved significantly faster than the typical multi-year patent litigation trajectory, suggesting the parties reached a negotiated commercial settlement that the court memorialized as a consent judgment. The March 2026 injunction end-date is notable — it may reflect an agreed wind-down period rather than an indefinite ban, though the public record does not disclose the full terms of the underlying settlement agreement. Whether financial compensation changed hands, and on what terms, remains confidential.
Filing to Consent Judgment in 357 days
357-day resolution — faster than the median U.S. patent infringement case at district court level
Consent judgment and injunction: what the resolution means for both parties
Consent judgment is a court-enforceable settlement
A consent judgment combines a private settlement with a binding court order. Unlike a simple dismissal, the court retains jurisdiction to enforce the permanent injunction. Here, defendants waived their right to appeal, making the injunction immediately final. Breach of the injunction can be treated as contempt of court — a significantly stronger enforcement tool than a contractual remedy alone.
Court-enforceable orderHydraFacial secures injunction without full trial risk
HydraFacial obtained the core commercial relief it sought — removal of the Bela MD and Bela MD+ products from the U.S. market — without bearing the cost and uncertainty of a full merits trial. The six asserted patents survive unchallenged; no invalidity finding was made. The consent judgment explicitly preserves HydraFacial’s rights against third parties, including manufacturers and distributors not named in this action.
Portfolio intact, injunction securedBela MD distribution halted through March 2026
The four defendant entities — Luvo Medical, Clarion Medical, Eunsung Global, and Healthcare Markets — are barred from all commercialisation of Bela MD and Bela MD+ in the U.S. through March 29, 2026. A narrow carve-out permits warranty fulfilment on previously distributed units. Defendants take nothing by way of judgment and waived all appellate rights, consistent with a negotiated exit rather than a contested merits defeat.
U.S. market exit agreedHydraFacial’s six-patent wall raises barriers for competing devices
The consent judgment reinforces HydraFacial’s multi-patent enforcement posture across its hydrodermabrasion portfolio. With six patents spanning device architecture and methods — and no invalidity challenge resolved on the merits — competing products face a strengthened IP perimeter. Companies distributing or manufacturing functionally similar devices in the U.S. should note that HydraFacial’s rights against non-parties are expressly preserved under paragraph 8 of the judgment.
Strengthened enforcement postureFull party and counsel information
| Role | Name | Type | Detail |
|---|---|---|---|
| Plaintiff | HydraFacial LLC | Company | Aesthetic device company — holder of six hydrodermabrasion patents including US9550052Search in Eureka ↗ |
| Defendant | Luvo Medical Technologies | Company | Medical device distributor of the Bela MD and Bela MD+ hydrodermabrasion systems and three co-defendant channel partnersSearch in Eureka ↗ |
| Co-Defendant | Clarion Medical Technologies Inc | Company | Search in Eureka ↗ |
| Co-Defendant | Eunsung Global Corp | Company | Search in Eureka ↗ |
| Co-Defendant | Healthcare Markets Inc | Company | Search in Eureka ↗ |
| Plaintiff counsel | Benjamin J. Everton | Attorney | Counsel for HydraFacial LLCSearch in Eureka ↗ |
| Plaintiff counsel | Chad S. Pehrson | Attorney | Counsel for HydraFacial LLCSearch in Eureka ↗ |
| Plaintiff counsel | Christian D. Boettcher | Attorney | Counsel for HydraFacial LLCSearch in Eureka ↗ |
| Plaintiff counsel | D. Craig Parry | Attorney | Counsel for HydraFacial LLCSearch in Eureka ↗ |
| Plaintiff law firm | Kunzler Bean & Adamson | Law Firm | Representing HydraFacial LLCSearch in Eureka ↗ |
| Plaintiff law firm | MORGAN LEWIS & BROCKIUS LLP | Law Firm | Representing HydraFacial LLCSearch in Eureka ↗ |
| Plaintiff law firm | PARR BROWN GEE & LOVELESS | Law Firm | Representing HydraFacial LLCSearch in Eureka ↗ |
| Defendant counsel | Jeffrey C. Bramble | Attorney | Counsel for Luvo Medical TechnologiesSearch in Eureka ↗ |
| Defendant counsel | Kevin N. Anderson | Attorney | Counsel for Luvo Medical TechnologiesSearch in Eureka ↗ |
| Defendant counsel | Luke Hartman | Attorney | Counsel for Luvo Medical TechnologiesSearch in Eureka ↗ |
| Defendant counsel | Steven P. Tepera | Attorney | Counsel for Luvo Medical TechnologiesSearch in Eureka ↗ |
| Defendant law firm | Fabian Vancott | Law Firm | Representing Luvo Medical TechnologiesSearch in Eureka ↗ |
| Defendant law firm | Pillsbury Winthrop Shaw Pittman, LLP | Law Firm | Representing Luvo Medical TechnologiesSearch in Eureka ↗ |
| Presiding judge | Judge Tena Campbell | Judge | Utah District CourtSearch in Eureka ↗ |
Official order — verbatim text
The consent judgment is notably comprehensive in scope: it binds defendants’ officers, directors, agents, affiliates, and all persons acting in concert — language designed to prevent circumvention through corporate restructuring or personnel changes. The explicit ‘colorably different’ standard extends the injunction beyond the named Bela MD products to functionally equivalent successors. Critically, the judgment makes no infringement or invalidity finding on the merits, preserving the six asserted patents’ presumption of validity in any future enforcement action. The bilateral appeal waiver in paragraph 9 is unusual and suggests both parties had strong incentives to achieve finality quickly.
HydraFacial’s six-patent hydrodermabrasion portfolio — US9550052 and five further patents
The six asserted patents — US9550052, US11446477, US11865287, US12053607, US10357641, and US10357642 — form a layered portfolio covering hydrodermabrasion device architecture, treatment methods, and component-level design across multiple application families. The portfolio spans application dates from US14/698673 through the more recent US18/487916, indicating a sustained multi-year prosecution strategy. Hydrodermabrasion technology combines mechanical exfoliation with simultaneous infusion of serums, representing a technically differentiated category within professional aesthetic devices.
HydraFacial’s decision to assert all six patents in a single action against the Bela MD product line reflects a deliberate portfolio-stacking strategy. By covering both apparatus and method claims across multiple continuation families, HydraFacial creates overlapping protection that makes design-arounds substantially more difficult and invalidity challenges more costly. For competitors operating in the professional hydrodermabrasion space — particularly those distributing Korean-manufactured devices in North America — this portfolio represents a material commercial risk requiring careful FTO analysis before any U.S. market entry.
Should you run an FTO against HydraFacial’s hydrodermabrasion patent portfolio?
Any company manufacturing, importing, or distributing professional hydrodermabrasion devices in the U.S. market — particularly devices combining vacuum-assisted exfoliation with simultaneous serum infusion — should treat this six-patent portfolio as a priority FTO target. The Bela MD enforcement action demonstrates that HydraFacial actively monitors and litigates against competing products, and paragraph 8 of the consent judgment signals that follow-on enforcement against non-parties remains live.
PatSnap Eureka’s FTO Search Agent allows R&D and product teams to map their device architecture against each of HydraFacial’s six asserted patents — covering both apparatus and method claims — and identify claim elements that may read on proposed product configurations. Eureka can surface continuation families, related prosecution history, and prior art that may inform validity analysis, giving IP counsel the intelligence needed to assess design-around options or licensing risk before U.S. launch.
Run a freedom-to-operate analysis on US11865287B2 to assess your product’s exposure
Run FTO in Eureka →Similar hydrodermabrasion and aesthetic device patent cases in U.S. district courts
Explore related patent infringement actions involving hydrodermabrasion devices, aesthetic medical technology, and multi-patent enforcement in U.S. district courts.
What this case signals for the aesthetic medical device IP landscape
HydraFacial’s rapid consent judgment sets a precedent for aggressive multi-patent enforcement in the hydrodermabrasion sector.
Multi-patent assertion bundles compress settlement timelines
Asserting six patents simultaneously — covering both device and method claims — dramatically increases a defendant’s litigation exposure and invalidity burden. The 357-day resolution suggests that the breadth of the patent bundle, rather than any single patent’s strength, was the primary driver of settlement. IP teams in aesthetic device markets should audit competing portfolios for similar layered assertion strategies.
Channel-partner co-defendants amplify commercial pressure
Naming distributors (Clarion Medical, Healthcare Markets) and the Korean manufacturer (Eunsung Global) alongside the primary importer (Luvo Medical) ensured the entire U.S. supply chain faced simultaneous litigation risk. This joint-defendant strategy is increasingly common in medical device enforcement and can accelerate settlement by making a coordinated market exit the path of least resistance for all parties.
HydraFacial v Luvo — key questions answered
HydraFacial asserted six patents: US9550052, US11446477, US11865287, US12053607, US10357641, and US10357642 — all covering hydrodermabrasion devices and methods. The accused products were the Bela MD and Bela MD+ systems distributed by Luvo Medical, Clarion Medical Technologies, Healthcare Markets Inc., and manufactured by Eunsung Global Corp.
The consent judgment permanently enjoins the defendants through March 29, 2026 from making, using, selling, offering for sale, or importing the Bela MD and Bela MD+ products or any colorably similar product in the United States. A limited carve-out permits warranty fulfilment on previously distributed units. Defendants take nothing by way of the judgment and waived all appellate rights.
The March 29, 2026 end-date is unusual for a permanent injunction and the public record does not disclose the reason. It may reflect a negotiated wind-down period, a redesign window, or terms in the confidential underlying settlement agreement — such as a future licence or royalty arrangement. IP professionals should monitor for post-March 2026 product re-entry by the defendant entities.
No. The consent judgment was entered by agreement without any merits adjudication. No finding of infringement or invalidity was made on the record. The six asserted patents retain their full presumption of validity and can be enforced against other parties in future proceedings.
Paragraph 7 of the consent judgment dismisses all claims and counterclaims not resolved by the injunction without prejudice. This means neither party is barred from re-asserting those claims in future litigation if circumstances warrant. However, given the bilateral appeal waiver and the scope of the injunction, re-litigation in the near term is unlikely absent a material breach of the settlement.
PatSnap Eureka searches patents and litigation data to answer instantly.